Art

J-GLOBAL ID：201902221782032406   Reference number：19A0019977

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study

肺癌におけるHER2エキソン20変異に対する新規HER2阻害剤,ポゾチニブの活性と後天性耐性の機序:in vitro研究【JST・京大機械翻訳】

Author (22)： Koga Takamasa (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Koga Takamasa (Department of Thoracic Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan) ,  Kobayashi Yoshihisa (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Kobayashi Yoshihisa (Department of Medical Oncology, Harvard Medical School, Boston, MA, United States) ,  Tomizawa Kenji (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Tomizawa Kenji (Department of Thoracic Surgery, Izumi City Hospital, Izumi, Japan) ,  Suda Kenichi (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Kosaka Takayuki (Department of Medical Oncology, Harvard Medical School, Boston, MA, United States) ,  Kosaka Takayuki (Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan) ,  Kosaka Takayuki (Lowe Center for Thoracic Oncology, Harvard Medical School, Boston, MA, United States) ,  Sesumi Yuichi (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Fujino Toshio (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Nishino Masaya (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Ohara Shuta (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Chiba Masato (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Shimoji Masaki (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Takemoto Toshiki (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan) ,  Suzuki Makoto (Department of Thoracic Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan) ,  Jaenne Pasi A. (Department of Medical Oncology, Harvard Medical School, Boston, MA, United States) ,  Jaenne Pasi A. (Lowe Center for Thoracic Oncology, Harvard Medical School, Boston, MA, United States) ,  Jaenne Pasi A. (Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, United States) ,  Mitsudomi Tetsuya (Department of Thoracic Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan)
Material： Lung Cancer
Volume： 126  Page： 72-79  Publication year： 2018 
JST Material Number： W3184A  ISSN： 0169-5002  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Oncogenic HER2 mutations are p...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0019977&from=J-GLOBAL&jstjournalNo=W3184A") }}

Thesaurus term： mutation ,  heat shock protein ,  therapeutic planning ,  *lung tumor ,  clinical trial ,  carcinogenicity ,  clone ,  EGF receptor ,  human(primates) ,  *variation(biology) ,  enzyme inhibitor
Semi thesaurus term： チロシンキナーゼ阻害剤 ,  肺腺癌 ,  *阻害剤 ,  *erbB-2受容体 , 【Automatic Indexing@JST】

Author keywords (6)： Lung cancer ,  HER2 mutation ,  Exon 20 ,  Poziotinib ,  Acquired resistance ,  C805S

JST classification (2)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A) ,  Chemistry,biochemistry and pathology of tumors(=neoplasms)  (GE02030N)

Substance index (1)： Erlotinib

Terms in the title (8)： 肺癌 ,  HER2 ,  エキソン ,  変異 ,  阻害剤 ,  活性 ,  耐性 ,  研究